3-bromo-5-ethylpyridin-2-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-bromo-5-ethylpyridin-2-amine
• 英文别名: 3-Bromo-5-ethylpyridin-2-amine
• 化学式: C₇H₉BrN₂
• 分子量: 201.066
• InChiKey: QFEJCZVFVPLJCN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
  申请人：Plexxikon Inc.

  公开号：US20140213554A1

  公开（公告）日：2014-07-31

  Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of the c-kit protein kinases and/or mutant c-kit protein kinases.

  本文介绍了对c-kit蛋白激酶或带有任何突变的突变c-kit蛋白激酶活性的化合物，以及制备和使用这些化合物治疗与c-kit蛋白激酶和/或突变c-kit蛋白激酶的异常活性相关的疾病和病状的方法。
• [EN] HETEROARYL INHIBITORS OF PLASMA KALLIKREIN<br/>[FR] INHIBITEURS HÉTÉROARYLE DE LA KALLICRÉINE PLASMATIQUE
  申请人：SHIRE HUMAN GENETIC THERAPIES

  公开号：WO2022197758A1

  公开（公告）日：2022-09-22

  The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

  本发明提供了一种化合物及其组合物，可用作血浆卡利肌酶的抑制剂，并表现出相同的理想特性。
• Bicyclic heterocyclic compound
  申请人：MITSUBISHI TANABE PHARMA CORPORATION

  公开号：US10793582B2

  公开（公告）日：2020-10-06

  Provided are a novel compound having a superior inhibitory action on KAT-II, a production method thereof, use thereof, and a pharmaceutical composition containing the aforementioned compound and the like. A compound represented by the formula (I) or a pharmacologically acceptable salt thereof. wherein each symbol is as defined in the DESCRIPTION.

  本发明提供了一种对 KAT-II 具有卓越抑制作用的新型化合物、其生产方法、其用途以及含有上述化合物的药物组合物等。 一种由式（I）代表的化合物或其药理学上可接受的盐。 其中各符号如说明书中所定义。
• 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER
  申请人：Lead Discovery Center GmbH

  公开号：EP3807274A1

  公开（公告）日：2021-04-21
• NOVEL BICYCLIC HETEROCYCLIC COMPOUND
  申请人：MITSUBISHI TANABE PHARMA CORPORATION

  公开号：US20190233438A1

  公开（公告）日：2019-08-01

  Provided are a novel compound having a superior inhibitory action on KAT-II, a production method thereof, use thereof, and a pharmaceutical composition containing the aforementioned compound and the like. A compound represented by the formula (I) or a pharmacologically acceptable salt thereof. wherein each symbol is as defined in the DESCRIPTION.